Search Results - "Girard, Emily J"

CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect by Crook, Zachary R., Sevilla, Gregory P., Young, Pamela, Girard, Emily J., Phi, Tinh-Doan, Howard, Monique L., Price, Jason, Olson, James M., Nairn, Natalie W.

“…Many disease-causing proteins have multiple pathogenic mechanisms, and conventional inhibitors struggle to reliably disrupt more than one. Targeted protein…”
Get full text

Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A by Hubert, Christopher G, Bradley, Robert K, Ding, Yu, Toledo, Chad M, Herman, Jacob, Skutt-Kakaria, Kyobi, Girard, Emily J, Davison, Jerry, Berndt, Jason, Corrin, Philip, Hardcastle, Justin, Basom, Ryan, Delrow, Jeffery J, Webb, Thomas, Pollard, Steven M, Lee, Jeongwu, Olson, James M, Paddison, Patrick J

“…To identify key regulators of human brain tumor maintenance and initiation, we performed multiple genome-wide RNAi screens in patient-derived glioblastoma…”
Get full text

BuGZ Is Required for Bub3 Stability, Bub1 Kinetochore Function, and Chromosome Alignment by Toledo, Chad M., Herman, Jacob A., Olsen, Jonathan B., Ding, Yu, Corrin, Philip, Girard, Emily J., Olson, James M., Emili, Andrew, DeLuca, Jennifer G., Paddison, Patrick J.

“…During mitosis, the spindle assembly checkpoint (SAC) monitors the attachment of kinetochores (KTs) to the plus ends of spindle microtubules (MTs) and prevents…”
Get full text

In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma by Whitehouse, Jacqueline P, Hii, Hilary, Mayoh, Chelsea, Wong, Marie, Ajuyah, Pamela, Barahona, Paulette, Cui, Louise, Dholaria, Hetal, White, Christine L, Buntine, Molly K, Byrne, Jacob, Rodrigues da Silva, Keteryne, Howlett, Meegan, Girard, Emily J, Tsoli, Maria, Ziegler, David S, Dyke, Jason M, Lee, Sharon, Ekert, Paul G, Cowley, Mark J, Gottardo, Nicholas G, Endersby, Raelene

“…Ependymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent…”
Get full text

Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys by Rupert, Peter B., Buerger, Matthew, Girard, Emily J., Frutoso, Marie, Parrilla, Don, Ng, Kevin, Gooley, Theodore, Groh, Veronika, Strong, Roland K.

“…NKG2D and its ligands are critical regulators of protective immune responses controlling infections and cancer, defining a crucial immune signaling axis…”
Get full text

FBXO42 activity is required to prevent mitotic arrest, spindle assembly checkpoint activation and lethality in glioblastoma and other cancers by Hoellerbauer, Pia, Kufeld, Megan, Arora, Sonali, Mitchell, Kelly, Girard, Emily J, Herman, Jacob A, Olson, James M, Paddison, Patrick J

“…Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. To identify genes differentially required for the viability of GBM stem-like cells…”
Get full text

Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells by Toledo, Chad M., Ding, Yu, Hoellerbauer, Pia, Davis, Ryan J., Basom, Ryan, Girard, Emily J., Lee, Eunjee, Corrin, Philip, Hart, Traver, Bolouri, Hamid, Davison, Jerry, Zhang, Qing, Hardcastle, Justin, Aronow, Bruce J., Plaisier, Christopher L., Baliga, Nitin S., Moffat, Jason, Lin, Qi, Li, Xiao-Nan, Nam, Do-Hyun, Lee, Jeongwu, Pollard, Steven M., Zhu, Jun, Delrow, Jeffery J., Clurman, Bruce E., Olson, James M., Paddison, Patrick J.

“…To identify therapeutic targets for glioblastoma (GBM), we performed genome-wide CRISPR-Cas9 knockout (KO) screens in patient-derived GBM stem-like cells…”
Get full text

Versatile tissue‐injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeutics by Nealy, Eric S., Reed, Steven J., Adelmund, Steven M., Badeau, Barry A., Shadish, Jared A., Girard, Emily J., Brasel, Kenneth, Pakiam, Fiona J., Mhyre, Andrew J., Price, Jason P., Sarkar, Surojit, Kalia, Vandana, DeForest, Cole A., Olson, James M.

“…Hydrogels are extensively employed in healthcare due to their adaptable structures, high water content, and biocompatibility, with FDA‐approved applications…”
Get full text

Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse by Zhang, Liguo, He, Xuelian, Liu, Xuezhao, Zhang, Feng, Huang, L. Frank, Potter, Andrew S., Xu, Lingli, Zhou, Wenhao, Zheng, Tao, Luo, Zaili, Berry, Kalen P., Pribnow, Allison, Smith, Stephanie M., Fuller, Christine, Jones, Blaise V., Fouladi, Maryam, Drissi, Rachid, Yang, Zeng-Jie, Gustafson, W. Clay, Remke, Marc, Pomeroy, Scott L., Girard, Emily J., Olson, James M., Morrissy, A. Sorana, Vladoiu, Maria C., Zhang, Jiao, Tian, Weidong, Xin, Mei, Taylor, Michael D., Potter, S. Steven, Roussel, Martine F., Weiss, William A., Lu, Q. Richard

“…Progenitor heterogeneity and identities underlying tumor initiation and relapse in medulloblastomas remain elusive. Utilizing single-cell transcriptomic…”
Get full text

A biobank of patient-derived pediatric brain tumor models by Brabetz, Sebastian, Leary, Sarah E. S., Gröbner, Susanne N., Nakamoto, Madison W., Şeker-Cin, Huriye, Girard, Emily J., Cole, Bonnie, Strand, Andrew D., Bloom, Karina L., Hovestadt, Volker, Mack, Norman L., Pakiam, Fiona, Schwalm, Benjamin, Korshunov, Andrey, Balasubramanian, Gnana Prakash, Northcott, Paul A., Pedro, Kyle D., Dey, Joyoti, Hansen, Stacey, Ditzler, Sally, Lichter, Peter, Chavez, Lukas, Jones, David T. W., Koster, Jan, Pfister, Stefan M., Kool, Marcel, Olson, James M.

“…Brain tumors are the leading cause of cancer-related death in children. Genomic studies have provided insights into molecular subgroups and oncogenic drivers…”
Get full text

ZNF131 suppresses centrosome fragmentation in glioblastoma stem-like cells through regulation of HAUS5 by Ding, Yu, Herman, Jacob A., Toledo, Chad M., Lang, Jackie M., Corrin, Philip, Girard, Emily J., Basom, Ryan, Delrow, Jeffrey J., Olson, James M., Paddison, Patrick J.

Get full text

Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models by Vitanza, Nicholas A, Biery, Matt C, Myers, Carrie, Ferguson, Eric, Zheng, Ye, Girard, Emily J, Przystal, Justyna M, Park, Giulia, Noll, Alyssa, Pakiam, Fiona, Winter, Conrad A, Morris, Shelli M, Sarthy, Jay, Cole, Bonnie L, Leary, Sarah E S, Crane, Courtney, Lieberman, Nicole A P, Mueller, Sabine, Nazarian, Javad, Gottardo, Raphael, Brusniak, Mi-Youn, Mhyre, Andrew J, Olson, James M

“…Abstract Background Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), have a dismal prognosis, with less than 2% surviving 5…”
Get full text

Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward by Mishra, Deepak Kumar, Popovski, Dean, Morris, Shelli M, Bondoc, Andrew, Senthil Kumar, Shiva, Girard, Emily J, Rutka, James, Fouladi, Maryam, Huang, Annie, Olson, James M, Drissi, Rachid

“…Abstract Brain tumors are the most common solid tumor in children and the leading cause of cancer-related deaths. Over the last few years, improvements have…”
Get full text

Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival by Crotty, Erin E., Smith, Stephanie M. C., Brasel, Ken, Pakiam, Fiona, Girard, Emily J., Connor, Yamicia D., Zindy, Frederique, Mhyre, Andrew J., Roussel, Martine F., Olson, James M.

“…Purpose Tumor infiltration by immunosuppressive myeloid cells or tumor-associated macrophages (TAMs) contributes to tumor progression and metastasis. In…”
Get full text

Target-to-background enhancement in multispectral endoscopy with background autofluorescence mitigation for quantitative molecular imaging by Yang, Chenying, Hou, Vivian W, Girard, Emily J, Nelson, Leonard Y, Seibel, Eric J

“…Fluorescence molecular imaging with exogenous probes improves specificity for the detection of diseased tissues by targeting unambiguous molecular signatures…”
Get full text

Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager by Crook, Zachary R, Girard, Emily J, Sevilla, Gregory P, Brusniak, Mi-Youn, Rupert, Peter B, Friend, Della J, Gewe, Mesfin M, Clarke, Midori, Lin, Ida, Ruff, Raymond, Pakiam, Fiona, Phi, Tinh-Doan, Bandaranayake, Ashok, Correnti, Colin E, Mhyre, Andrew J, Nairn, Natalie W, Strong, Roland K, Olson, James M

“…Cystine-dense peptides (CDPs) are a miniprotein class that can drug difficult targets with high affinity and low immunogenicity. Tools for their design,…”
Get more information

Pacifastin-derived Peptides Target Tumors for Use in In Vivo Imaging by Sottero, Theo L, Girard, Emily J, Myers, Carrie, Hopping, Gene, Mhyre, Andrew J, Olson, James M

“…Developments in imaging have improved cancer diagnosis, but identification of malignant cells during surgical resection remains a challenge. The aim of this…”
Get full text

Calibration of fluorescence imaging for tumor surgical margin delineation: multistep registration of fluorescence and histological images by Jiang, Yang, Girard, Emily J, Pakiam, Fiona, Seibel, Eric J

“…Although a greater extent of tumor resection is important for patients' survival, complete tumor removal, especially tumor margins, remains challenging due to…”
Get full text

A technology platform to assess multiple cancer agents simultaneously within a patient's tumor by Klinghoffer, Richard A, Bahrami, S Bahram, Hatton, Beryl A, Frazier, Jason P, Moreno-Gonzalez, Alicia, Strand, Andrew D, Kerwin, William S, Casalini, Joseph R, Thirstrup, Derek J, You, Sheng, Morris, Shelli M, Watts, Korashon L, Veiseh, Mandana, Grenley, Marc O, Tretyak, Ilona, Dey, Joyoti, Carleton, Michael, Beirne, Emily, Pedro, Kyle D, Ditzler, Sally H, Girard, Emily J, Deckwerth, Thomas L, Bertout, Jessica A, Meleo, Karri A, Filvaroff, Ellen H, Chopra, Rajesh, Press, Oliver W, Olson, James M

“…A fundamental problem in cancer drug development is that antitumor efficacy in preclinical cancer models does not translate faithfully to patient outcomes…”
Get more information

Abstract LB-231: An optide (optimized knottin-peptide) that inhibits tumor cell growth In vitro and accumulates in sarcoma flank tumors in vivo by Sottero, Theo, Girard, Emily J., Correnti, Colin, Stroud, Mark R., Kier, Brandon L., Mhyre, Andrew J., Olson, James

“…Abstract Antibody-drug conjugates (ADCs) have been FDA approved for the targeted delivery of chemotherapy to cancer. However, ADCs are limited for solid tumors…”
Get full text